Loading clinical trials...
Loading clinical trials...
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell car...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
NCT03288545 · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, and more
NCT03219333 · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, and more
NCT02443324 · Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, and more
NCT06305130 · Carcinoma, Transitional Cell (RENI)
NCT02450331 · Carcinoma, Transitional Cell
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions